News

The initial products will be directed to the ovarian cancer biomarker, HE4, which is FDA-cleared for monitoring the progression or recurrence of epithelial ovarian cancer. Fujirebio also grants

Alton Boynton, Northwest Biotherapeutics’s CEO, said: “We are very pleased to have completed another interim financing despite severely adverse general market conditions. We look forward to continuing the

ELISA is provided with all reagents required including a pre-coated microplate eliminating the need for an overnight incubation found with other commercially available kits. Results are achieved in

Total revenues in 2008 were $4.1 billion, an increase of 29% from $3.2 billion in 2007. The company has reported net income of $207 million for the fourth

The study is a multi-center, open-label, randomized two-period crossover comparison of ANX-514 and Taxotere, with a primary endpoint of pharmacokinetic equivalence of ANX-514 and Taxotere and a goal

The application for traditional approval includes 48-week data from two Phase III studies known as Duet-1 and Duet-2. Intelence is currently marketed in the US by Tibotec Therapeutics,

Tigris in-licensed the exclusive worldwide rights to GGTI-2418 from Yale University and the University of South Florida. Edmundo Muniz, president and CEO of Tigris, said: The filing of

Under the terms of the agreement, entered into in December 2005, the companies are collaborating to discover and develop novel Nanobody-based therapeutics against disease targets that are difficult

hPAM4 is a humanized monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancer, but not pancreatitis, normal pancreas or most other normal tissues.